Recent

% | $
Quotes you view appear here for quick access.

Discovery Laboratories Inc. Message Board

thebostonangler 33 posts  |  Last Activity: Mar 26, 2015 12:10 PM Member since: Aug 22, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • thebostonangler by thebostonangler Mar 26, 2015 12:10 PM Flag

    I was going to get some more in the .04s.... Oh well

    B/A

  • thebostonangler by thebostonangler Mar 23, 2015 6:09 PM Flag

    I recall someone telling me we'd never see .10 again on the last run up. Hmmmm My reply was simple Vroom Vroom! I got in at .04 and sold at .17. I believe we are getting to the point to do it again... We break .05 and I'm doubling down. Not telling folks what to do, just giving my personal opinion. But I do like the action with AMBS... It should be called ATMS

  • thebostonangler thebostonangler Mar 3, 2015 2:47 PM Flag

    I'm not sure

  • Regenicin, Inc. a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has received the final payment to conclude The Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: AMBS).

    As required under the Agreement, Amarantus made the final payments due to Regenicin in the amount of $2.3 Million, along with a payment of $200,000 to Regenicin's senior secured creditor. In addition, Regenicin with Amarantus and Lonza Group, Ltd and its related entities, have signed a Settlement Agreement in the company's lawsuit with Lonza Group, Ltd and its related entities. Regenicin has filed a joint dismissal of all claims, known or unknown, in the Lonza matter.

    The Company is pleased to announce the completion of the Asset Purchase Agreement with the final payments being made by Amarantus on February 25, 2015. The PermaDerm trademark has been transferred and all obligations by all parties have been completed.

    Regenicin values The Asset Purchase Agreement transaction with Amarantus at $8.023 million, comprised of $3.075 million in cash, $3.0 million in Amarantus restricted stock, and payments and forgiveness of liabilities and notes totaling, $1.948 million. It should be noted that the Amarantus stock is restricted from sale until May 7, 2015.

    Management believes that this transaction will provide Regenicin adequate funding to continue product development of life saving technology. It is estimated that the proceeds should bring us to the initiation of FDA sanctioned clinical trials with our first cell therapy wound care product.

    "We are excited to have the Asset Purchase Agreement completed," says Randall McCoy CEO of Regenicin. "We are now well positioned to establish Regenicin's own cell therapy product in the FDA approval pipeline."

  • thebostonangler thebostonangler Feb 27, 2015 3:14 PM Flag

    Where are you getting this news of increasing shares? I can't find it

  • thebostonangler thebostonangler Feb 26, 2015 10:44 AM Flag

    I don't understand. They would want to buyback at the lowest price, but after March 31st wouldn't they woant the price to go up?

    B/A

  • thebostonangler by thebostonangler Feb 26, 2015 10:42 AM Flag

    Buyback increased to 2 Billion shares.
    Under the Tender Offer, shareholders will have the opportunity to tender some, or all of their shares, at a price within the range of $0.0001 to $0.01 per share. The Tender Offer will not be contingent upon a minimum number of shares being tendered and will be subject to a number of other terms and conditions specified in the offer to purchase.

    The company is working with the transfer agent to provide for shareholders to electronically tender their shares through their brokerage accounts.

    The company, its board of directors or its advisors, will not be making any recommendation to shareholders as to whether to tender, or refrain from tendering their shares, into the Tender Offer.

    The company's directors and executive officers have advised the company that they do not intend to tender any of their shares they own, or control, in the tender offer.

    B/A

  • Reply to

    FINALE----CURTAIN CLOSED

    by buickelectra444 Feb 24, 2015 2:56 PM
    thebostonangler thebostonangler Feb 24, 2015 4:51 PM Flag

    What happened to it's gonna take off? Guess you missed it BIG TIME!

  • thebostonangler by thebostonangler Feb 23, 2015 8:26 AM Flag

    SAINT LAURENT, Quebec, Feb. 23, 2015 (GLOBE NEWSWIRE) -- IntelGenx Corp. ("IntelGenx", or the "Company") today provided an update on sales and marketing activities for Forfivo XL(R), the Company's first FDA-approved product that was launched in the USA in October 2012 under an exclusive commercialization agreement with Edgemont Pharmaceuticals LLC ("Edgemont").

    According to Symphony Health Solutions, gross sales of Forfivo XL(R) totaled $8.9 million in the year ending December 31st, 2014, an increase of 230% compared with sales of $2.7 million in the preceding year. The number of Forfivo XL(R) prescriptions filled increased by 123% from approximately 16,761 in 2013 to 30,378 in 2014. The average month-on-month growth rate of Forfivo XL(R) throughout 2014 exceeded 9%.

    "We are extremely pleased with the growth of Forfivo XL(R) throughout 2014 and we believe that this growth will continue, especially as Edgemont increased its salesforce threefold in mid-December, 2014" stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "The marketing and sales efforts that our partner, Edgemont Pharmaceuticals, has invested in the commercialization of Forfivo XL(R) have ensured that a more convenient and safe alternative for patients requiring high-dose anti-depressant therapy is widely available in the US. Forfivo XL(R) generated in excess of $1.1 million (unaudited) of revenue for IntelGenx in 2014 and we anticipate significantly higher revenue from the product in 2015."

    Forfivo XL(R) is indicated for treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL(R) is bupropion, the same active ingredient used in the well-known antidepressant product: Wellbutrin XL(R).

  • thebostonangler by thebostonangler Feb 20, 2015 10:56 AM Flag

    Worldwide Diversified Holdings, Inc. announced today that is has filed the materials with OTC Markets for its stock buyback program to repurchase up to one billion common shares.

    The company will commence a Dutch Auction Tender Offer (the "Tender Offer") to repurchase the shares on March 3, 2015 with the expiration of the offer on 5pm EDT on March 31, 2015. The shareholders will have the opportunity to tender some, or all of their shares, at a price within the range of $0.0001 to $0.01 per share.

    This release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of the Company's common stock. The solicitation and offer to buy the Company's common stock will only be made pursuant to the offer to purchase and related materials that the Company will provide to its shareholders. Shareholders should read those materials carefully because they will contain important information, including the various terms and conditions of the Tender Offer

  • Reply to

    News!

    by nj46nick Feb 18, 2015 11:02 AM
    thebostonangler thebostonangler Feb 18, 2015 11:15 AM Flag

    BOOM!

    B/A

  • thebostonangler by thebostonangler Feb 13, 2015 11:14 AM Flag

    Announced today that it is implementing a stock buyback program to repurchase up to one billion common shares.
    The company will commence a Dutch Auction Tender Offer (the "Tender Offer") to repurchase the shares on March 3, 2015 with the expiration of the offer, unless extended, will be 5pm EST on March 31, 2015.
    Under the Tender Offer, shareholders will have the opportunity to tender some, or all of their shares, at a price within the range of $0.0001 to $0.01 per share. Based on the number of shares tendered and the prices specified by the tendering shareholders, the company will determine the lowest per share price within the range that will enable it to buy up to one billion common shares.
    The Tender Offer will not be contingent upon a minimum number of shares being tendered and will be subject to a number of other terms and conditions specified in the offer to purchase.
    The company, its board of directors or its advisors, will not be making any recommendation to shareholders as to whether to tender, or refrain from tendering their shares, into the Tender Offer.
    The company's directors and executive officers have advised the company that they do not intend to tender any of their shares they own, or control, in the tender offer.
    Commenting on the announcement, Frank Kristan, President, stated, "This tender offer underscores our commitment to enhancing shareholder value. It also represents an opportunity for the company to deliver value to those stockholders who elect to tender their shares, while at the same time increasing the proportional ownership of non-tendering stockholders."

  • thebostonangler by thebostonangler Feb 10, 2015 11:09 AM Flag

    NEW YORK, NY--(Marketwired - Feb 10, 2015) - Worldwide Diversified Holdings, Inc. (OTC PINK: WNTR) announced today that its portfolio company I-Texts, Inc. has appointed Transfer Online, Inc., a leading stock transfer agency and technology firm, as the corporation's stock transfer agent and registrar.

    I-Texts, Inc. will benefit from Transfer Online, Inc.'s innovative web-based proprietary stock transfer system that provides self-service functions to include reporting, stock issuances, stock offerings, press releases, and Edgar/XBRL filing. In addition, Transfer Online, Inc.'s software and pricing caters to new startups and is easily configurable to any crowd funding platform.

    "Our customers have come to depend on us to provide easy-to-use online services that take the traditional transfer agent services and automate them. Our system is user friendly, available 24/7 and secure," said Lori Livingston, Transfer Online, Inc. President & CEO. "We continue to push the envelope when it comes to providing transfer agent services. By applying the latest technologies we are able to pass on significant savings to our clients."

    The company is working with Transfer Online to issue the dividend shares for holders of the Worldwide Diversified Holdings, Inc. common stock.

  • Reply to

    5 cents first!

    by letitgrowknows Feb 3, 2015 3:27 PM
    thebostonangler thebostonangler Feb 4, 2015 5:22 PM Flag

    Walking her slowly... I like it!

    B/A

  • thebostonangler by thebostonangler Jan 27, 2015 12:21 PM Flag

    That this is coming to an end.... Too bad the product is a great idea. I just moved some over to SING it looks like it could be a nice ride. JMHO

    B/A

  • thebostonangler by thebostonangler Jan 27, 2015 9:42 AM Flag

    I love this company... It is an undiscovered gem!

    B/A

  • thebostonangler by thebostonangler Jan 23, 2015 11:03 AM Flag

    SEATTLE, WA--(Marketwired - Jan 23, 2015) - SinglePoint, Inc. is pleased to announce that it has completed its acquisition of GreenStar Payment Solutions, Inc. (GreenStar) from former venture partners, GreenHouse Payment Solutions and New Wave Holdings, Inc. (fka Advanced Content Services, Inc.).

    GreenStar is now a wholly owned subsidiary of SinglePoint and will be leveraged as a brand servicing the legalized cannabis industry with a number of service-based laterals for business owners in the space. SinglePoint CEO Greg Lambrecht states, "We are happy to have this completed. We can now move forward to fully position and utilize the brand for further reach into its respective markets including dispensaries and retail."

    SinglePoint is gearing to distribute more than just payments through the GreenStar brand and will be restructuring the company as a distribution and product placement company. "The company has accumulated many contacts in the last year and we believe we can place more than just payment solutions in stores around the nation," adds Lambrecht. GreenStar is currently working on placement deals and will update shareholders in the coming days with an overview of the subsidiary's new platform.

  • thebostonangler by thebostonangler Jan 22, 2015 3:57 PM Flag

    NEW YORK, NY--(Marketwired - Jan 22, 2015) - Worldwide Diversified Holdings, Inc. announced today that it has received $2.4 million in funding commitments as part of the acquisition of Lemaro Investments from Venerable Capital Corporation.

    The funding will be used for portfolio investments and working capital. It will also allow the company to complete the listing process that will include a buyback of its shares in association with a dual listing on the OTC markets and a major exchange.

    The company also announced the GCHI Green Company Holdings, Inc. is in final negotiations for its public listing and an announcement will be made in the near future. The company confirmed that I-Texts, Inc. has appointed a transfer agent for the issuance of the dividend shares.

    Frank Kristan, President of Worldwide Diversified Holdings, Inc., stated, "We are pleased that we have received the financing commitment to be able to complete our listing and implement a strategy to increase shareholder value."

  • Reply to

    Late Stage Discussions With Pharma's ?

    by tom.prohaska Jan 22, 2015 10:06 AM
    thebostonangler thebostonangler Jan 22, 2015 3:54 PM Flag

    I'd say new members to advisory board are there to protect the interest of interested parties. You don't buy or invest in something without taking it for a test drive... So to speak.

    B/A

  • thebostonangler by thebostonangler Jan 13, 2015 3:44 PM Flag

    Terms of the deal very favorable for Amarantus

    As payment for acquiring DioGenix, Amarantus is issuing registered shares of common stock valued at $8 million as well as paying up to $900,000 for associated transaction costs. In addition, Amarantus will pay up to $2 million in milestone payments based on the achievement of sales milestones. In conjunction with the transaction, Amarantus completed the Series E Preferred Stock offering and raised an additional $1 million, with the funds to be used to pay for the costs associated with the closing of the DioGenix acquisition.

    Importantly, in November 2014 DioGenix was awarded a $7.45 million “Grow NJ Assistance Tax Credit” to facilitate the construction of a laboratory in Camden, NJ. These tax credits can be sold in whole or in part for a minimum of 75% of face value (≥ $5.6 million). Amarantus is intending on evaluating the possible sale of these credits, which could potentially drive the total acquisition cost of this deal down to approximately $2 million.

    Conclusion

    We believe MSPrecise® is a good fit for Amarantus and will serve as a solid foundation upon which to build a successful diagnostics business. As we mentioned in our “15 Biotech Name for 2015” article, Amarantus has been discussing the possibility of spinning out LymPro into a separately traded diagnostic division in 2015. In the article we state that the company would need to package LymPro with another diagnostic product in CNS, and we believe that MSPrecise® certainly fits the criteria. At this point, we would not be surprised to see the spin-out of Amarantus Diagnostics sometime in the next six months, a move we feel could unlock significant value for shareholders.

DSCO
1.17+0.02(+1.74%)Mar 27 4:00 PMEDT